Obesity, a cause of subclinical inflammation, is associated with increased risk of high-grade prostate cancer (PC) and poor outcomes. Whether inflammation occurs in periprostatic white adipose tissue (WAT)...
Background: Biochemical recurrence (BCR) is widely used to define the treatment success and to make decisions on if or how to initiate a secondary therapy, but uniform criteria to define BCR after radical prostatectomy (RP) is not yet completely assessed.
Men who receive anti-hormonal treatment after having their prostate removed are 80% more likely to suffer from depression than men who don’t receive this treatment.
Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level.
US researchers have shown that testosterone replacement slows the recurrence of prostate cancer in low-risk patients.
Purpose: We assessed the midterm oncologic outcomes of vascular targeted photodynamic therapy with padeliporfin for low risk prostate cancer treatment.
GenomeDx Biosciences announced the first validation data supporting use of the Decipher Prostate Cancer Classifier in analysis of diagnostic needle...
There is a great need to identify new and better prognostic and predictive biomarkers to stratify prostate cancer patients for optimal treatment.
Hyperbaric oxygen therapy (HBOT) has been used as an adjuvant treatment for multiple pathological states, which involves hypoxic conditions.
Latest research presented at the 32nd Annual EAU Congress held in London from 24-28 March 2017.